pDRIVE-AFP / hAFP
| Product | Unit size | Cat. code | Docs. | Qty. | Price | |
|---|---|---|---|---|---|---|
|
pDRIVE-AFP-hAFP pDRIVE bearing human AFP / hAFP promoter - LacZ |
Show product |
20 µg |
pdrive-afphafp
|
|
||
|
pDRIVE5SEAP-AFP-hAFP pDRIVE bearing human AFP / hAFP promoter - SEAP |
Show product |
20 µg |
pdrive5s-afphafp
|
|
||
|
pDRIVE5Lucia-AFP-hAFP pDRIVE bearing human AFP / hAFP promoter - Lucia |
Show product |
20 µg |
pdrive5lc-afphafp
|
|
Alpha-fetoprotein (AFP) enhancer and promoter in pDRIVE expression plasmid
The alpha-fetoprotein (AFP) gene is normally expressed in fetal but not adult livers. However, about 70% of hepatocellular carcinoma (HCC) are known to overexpress AFP, this up-regulation occurring at the transcriptional level.
The AFP promoter has been extensively studied and shown to confer a selective expression of a transgene in vitro and in vivo [1]. The expression level of the transgene is proportional to the level of AFP expression in the transfected cells [2].
Several studies have reported the use of AFP promoter to express a cytokine or suicide gene into HCC cells after delivery with viral or plasmid vectors [1, 2].
References:
1. Kanai F. et al. 1997. In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res. 57(3):461-5.
2. He P. et al. 2000. The targeted expression of interleukin-2 in human hepatocellular carcinoma cells. J Exp Clin Cancer Res. 19(2):183-7.
Specifications
pDRIVE bearing human AFP / hAFP promoter - LacZ, SEAP or Lucia
Gene Promoter: AFP: Alpha-Fetoprotein
Specificity: Hepatocellular carcinoma
Backbone: pDRIVE, pDRIVE5-SEAP or pDRIVE5-Lucia
Selection: Zeocin™
pDRIVE contents
- 20 µg of lyophilized DNA
- 1 ml of Zeocin™ (100 mg/ml)
Product is shipped at room temperature
